{"disease":{"id":"hodgkin-disease-refractory","name":"hodgkin disease refractory"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04776265","title":"RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Grupo Argentino de Tratamiento de la Leucemia Aguda","has_results":false},{"nct_id":"NCT06712810","title":"Q702 for the Treatment of Patients With Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03333486","title":"Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05352828","title":"Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Tessa Therapeutics","has_results":false},{"nct_id":"NCT04938232","title":"Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT03096782","title":"Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}